MARKET

IDXG

IDXG

Interpace Biosciences Inc
OTCQX
2.470
-0.080
-3.14%
Closed 15:35 06/02 EDT
OPEN
2.550
PREV CLOSE
2.550
HIGH
2.550
LOW
2.440
VOLUME
2.15K
TURNOVER
5.36K
52 WEEK HIGH
10.51
52 WEEK LOW
0.510
MARKET CAP
10.36M
P/E (TTM)
-0.4767
1D
5D
1M
3M
1Y
5Y
Interpace Biosciences GAAP EPS of $0.10, revenue of $9.8M
Seeking Alpha · 05/12 20:28
BRIEF-Interpace Biosciences Announces Record First Quarter 2023 Financial And Business Results
Reuters · 05/12 20:09
Interpace Biosciences GAAP EPS of -$0.33, revenue of $8.33M
Seeking Alpha · 03/27 21:18
-- Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $8.3M
-- Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $8.3M
MT Newswires · 03/27 16:14
Interpace Biosciences GAAP EPS of $3.35, revenue of $8.2M
Seekingalpha · 11/14/2022 22:49
-- Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q3 Revenue $8.19M
-- Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q3 Revenue $8.19M
MT Newswires · 11/14/2022 17:02
Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting
PARSIPPANY, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improv...
GlobeNewswire · 10/20/2022 20:28
Interpace Biosciences CFO Thomas Freeburg Resigns
Interpace Biosciences CFO Thomas Freeburg Resigns
MT Newswires · 10/04/2022 16:31
More
About IDXG
Interpace Biosciences, Inc., formerly Interpace Diagnostics Group, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, it provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Webull offers kinds of Interpace Biosciences Inc stock information, including OTCQX:IDXG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDXG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IDXG stock methods without spending real money on the virtual paper trading platform.